Evaluation of The Cost Effectiveness of Rifaximin-á 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In Sweden
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.2202
https://www.valueinhealthjournal.com/article/S1098-3015(15)04278-3/fulltext
Title :
Evaluation of The Cost Effectiveness of Rifaximin-á 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In Sweden
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04278-3&doi=10.1016/j.jval.2015.09.2202
First page :
A626
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
1620